Anidulafungin and its role in candida infections

References

• WisplinghoffHBischoffTTallentSMSeifertHWenzelRPEdmondMBNosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance studyClin Infect Dis20043930931715306996
   PubMed Web of Science ®Google Scholar
• SmithMJCatheter-related bloodstream infections in childrenAmer J Infect Contr200836S173.e171S173.e173
   Google Scholar
• MartinGSManninoDMEatonSMossMThe epidemiology of sepsis in the United States from 1979 through 2000N Engl J Med20033481546155412700374
   PubMed Web of Science ®Google Scholar
• ZilberbergMDShorrAFKollefMHSecular trends in candidemia-related hospitalization in the United States, 2000–2005Infect Control Hosp Epidemiol20082997898018715153
   PubMed Web of Science ®Google Scholar
• RichardsonMDChanging patterns and trends in systemic fungal infectionsJ Antimicrob Chemother200556i51116120635
   PubMed Web of Science ®Google Scholar
• PappasPGKauffmanCAAndesDClinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of AmericaClin Infect Dis20094850319191635
   PubMed Web of Science ®Google Scholar
• PfizerIEraxis (anidulafungin) package insertNew York, NY2007
   Google Scholar
• BartizalKGillCJAbruzzoGKIn vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)Antimicrob Agents Chemother199741232623329371328
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI)Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard3rd. edWayne, PA2008
   Google Scholar
• Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST)EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia–forming mouldsClin Microbiol Infect20081498298418828858
   PubMed Web of Science ®Google Scholar
• PfallerMABoykenLHollisRJMesserSATendolkarSDiekemaDJIn vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazoleJ Clin Microbiol2005435425542716272464
   PubMed Web of Science ®Google Scholar
• Ostrosky-ZeichnerLRexJHPappasPGAntifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United StatesAntimicrob Agents Chemother2003473149315414506023
   PubMed Web of Science ®Google Scholar
• PfallerMADiekemaDJMesserSAHollisRJJonesRNIn vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolatesAntimicrob Agents Chemother2003471068107112604543
   PubMed Web of Science ®Google Scholar
• Cuenca-EstrellaMRodriguezDAlmiranteBIn vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002–2003J Antimicrob Chemother20055519419915618284
   PubMed Web of Science ®Google Scholar
• MaligieMASelitrennikoffCPCryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandinsAntimicrob Agents Chemother2005492851285615980360
   PubMed Web of Science ®Google Scholar
• PfallerMAMarcoFMesserSAJonesRNIn vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungiDiagn Microbiol Infect Dis1998302512559582584
   PubMed Web of Science ®Google Scholar
• SerranoMdCValverde-CondeAChavezMMIn vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus sppDiagn Microbiol Infect Dis20034513113512614985
   PubMed Web of Science ®Google Scholar
• DiekemaDJMesserSAHollisRJJonesRNPfallerMAActivities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungiJ Clin Microbiol2003413623362612904365
   PubMed Web of Science ®Google Scholar
• ArikanSYurdakulPHascelikGComparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus sppAntimicrob Agents Chemother2003472640264312878531
   PubMed Web of Science ®Google Scholar
• OdabasiZPaetznickVLRodriguezJRChenEOstrosky-ZeichnerLIn vitro activity of anidulafungin against selected clinically important mold isolatesAntimicrob Agents Chemother2004481912191515105159
   PubMed Web of Science ®Google Scholar
• Schuetzer-MuehlbauerMWillingerBKrapfGEnzingerSPresterlEKuchlerKThe Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofunginMolecul Microbiol200348225235
   PubMed Web of Science ®Google Scholar
• NiimiKMakiKIkedaFOverexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibilityAntimicrob Agents Chemother2006501148115516569823
   PubMed Web of Science ®Google Scholar
• ParkSKellyRKahnJNSpecific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida spp. isolatesAntimicrob Agents Chemother2005493264327316048935
   PubMed Web of Science ®Google Scholar
• DouglasCMD’IppolitoJASheiGJIdentification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitorsAntimicrob Agents Chemother199741247124799371352
   PubMed Web of Science ®Google Scholar
• BalashovSVParkSPerlinDSAssessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1Antimicrob Agents Chemother2006502058206316723566
   PubMed Web of Science ®Google Scholar
• Garcia-EffronGKatiyarSKParkSEdlindTDPerlinDSA Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin SusceptibilityAntimicrob Agents Chemother2008522305231218443110
   PubMed Web of Science ®Google Scholar
• PerlinDSResistance to echinocandin-class antifungal drugsDrug Resistance Updates20071012117569573
   PubMed Web of Science ®Google Scholar
• KahnJNGarcia-EffronGHsuMJParkSMarrKAPerlinDSAcquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthaseAntimicrob Agents Chemother200751187617325225
   PubMed Web of Science ®Google Scholar
• GhannoumMAChenABuhariMDifferential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unitClin Microbiol Iinfect200915274
   PubMed Web of Science ®Google Scholar
• MoudgalVLittleTBoikovDVazquezJAMultiechinocandin- and Multiazole-Resistant Candida parapsilosis Isolates Serially Obtained during Therapy for Prosthetic Valve EndocarditisAntimicrob Agents Chemother20054976776915673762
   PubMed Web of Science ®Google Scholar
• MillerCDLomaestroBWParkSPerlinDSProgressive esophagitis caused by Candida albicans with reduced susceptibility to caspofunginPharmacother200626877880
   PubMed Web of Science ®Google Scholar
• LaverdiereMLalondeRGBarilJGSheppardDCParkSPerlinDSProgressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitisJ Antimicrob Chemother20065770570816464893
   PubMed Web of Science ®Google Scholar
• HernandezSLopez-RibotJLNajvarLKMcCarthyDIBocanegraRGraybillJRCaspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitisAntimicrob Agents Chemother2004481382138315047549
   PubMed Web of Science ®Google Scholar
• Krogh-MadsenMArendrupMCHesletLKnudsenJDAmphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patientClin Infect Dis20064293894416511756
   PubMed Web of Science ®Google Scholar
• HakkiMStaabJFMarrKAEmergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapyAntimicrob Agents Chemother2006502522252416801435
   PubMed Web of Science ®Google Scholar
• PasqualeTTomadaJRGhannounMDipersioJBonillaHEmergence of Candida tropicalis resistant to caspofunginJ Antimicrob Chemother20086121918024953
   PubMed Web of Science ®Google Scholar
• ArendrupMCGarcia-EffronGBuzinaWBreakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testingAntimicrob Agents Chemother200953118519104024
   PubMed Web of Science ®Google Scholar
• Cuenca-EstrellaMMooreCBBarchiesiFMulticenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST)Clin Microbiol Iinfect20039467
   PubMed Web of Science ®Google Scholar
• Cuenca-EstrellaMArendrupMCChryssanthouEMulticentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST)Clin Microbiol Iinfect2007131018
   Web of Science ®Google Scholar
• National Committee for Clinical Laboratory StandardsReference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard M27-A22nd edNational Committee for Clinical Laboratory StandardsWayne, PA2002
   Google Scholar
• PaderuPGarcia-EffronGBalashovSDelmasGParkSPerlinDSSerum Differentially Alters the Antifungal Properties of Echinocandin DrugsAntimicrob Agents Chemother2007512253225617420211
   PubMed Web of Science ®Google Scholar
• OdabasiZPaetznickVRexJHOstrosky-ZeichnerLEffects of serum on in vitro susceptibility testing of echinocandinsAntimicrob Agents Chemother2007514214421617785512
   PubMed Web of Science ®Google Scholar
• Garcia-EffronGParkSPerlinDSCorrelating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpointsAntimicrob Agents Chemother20095311212218955538
   PubMed Web of Science ®Google Scholar
• DowellJAStogniewMKrauseDSHenkelTAnidulafungin (ANID) pharmacokinetic (PK)/Pharmacodynamic (PD) correlation: Treatment of esophageal candidiasis (EC)43rd Interscience Conference on Antimicrob Agents ChemotherWashington, DCAmerican Society of Microbiology2003A1578
   Google Scholar
• GrollAHMickieneDPetraitieneRPharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma samplingAntimicrob Agents Chemother2001452845285511557479
   PubMed Web of Science ®Google Scholar
• AndesDDiekemaDJPfallerMAIn vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis modelAntimicrob Agents Chemother20085253955018070979
   PubMed Web of Science ®Google Scholar
• ErnstEJRolingEEPetzoldCRKeeleDJKlepserMEIn vitro activity of micafungin (FK-463) against Candida spp: microdilution, time-kill, and postantifungal-effect StudiesAntimicrob Agents Chemother2002463846385312435687
   PubMed Web of Science ®Google Scholar
• ErnstEJKlepserMEPfallerMAPostantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformansAntimicrob Agents Chemother2000441108111110722525
   PubMed Web of Science ®Google Scholar
• HallGSMylesCPrattKJWashingtonJACilofungin (LY121019), an antifungal agent with specific activity against Candida albicans and Candida tropicalisAntimicrob Agents Chemother198832133113353058017
   PubMed Web of Science ®Google Scholar
• RamageGVandeWalleKBachmannSPWickesBLLopez-RibotJLIn vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studiesAntimicrob Agents Chemother2002463634363612384379
   PubMed Web of Science ®Google Scholar
• WiederholdNPKontoyiannisDPChiJPrinceRATamVHLewisREPharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activityJ Infect Dis20041901464147115378439
   PubMed Web of Science ®Google Scholar
• StevensDAEspirituMParmarRParadoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrationsAntimicrob Agents Chemother2004483407341115328104
   PubMed Web of Science ®Google Scholar
• DamleBDDowellJAWalskyRLWeberGLStogniewMInskeepPBIn vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafunginAntimicrob Agents Chemother200953114919029327
   PubMed Web of Science ®Google Scholar
• DowellJAKnebelWLuddenTStogniewMKrauseDHenkelTPopulation pharmacokinetic analysis of anidulafungin, an echinocandin antifungalJ Clin Pharmacol20044459059815145966
   PubMed Web of Science ®Google Scholar
• DowellJAStogniewMKrauseDDamleBAnidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairmentJ Clin Pharmacol20074746147017389555
   PubMed Web of Science ®Google Scholar
• BenjaminDKJrDriscollTSeibelNLSafety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infectionsAntimicrob Agents Chemother20065063263816436720
   PubMed Web of Science ®Google Scholar
• KrauseDSSimjeeAEvan RensburgCA randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasisClin Infect Dis20043977015472806
   PubMed Web of Science ®Google Scholar
• VazquezJASchranzJAClarkKGoldsteinBPReboliAFichtenbaumCA phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasisJ Acquir Immune Defic Syndr20084830430918545153
   PubMed Web of Science ®Google Scholar
• KrauseDSReinhardtJVazquezJAPhase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemiaAntimicrob Agents Chemother2004482021202415155194
   PubMed Web of Science ®Google Scholar
• ReboliACRotsteinCPappasPGAnidulafungin versus fluconazole for invasive candidiasisN Engl J Med20073562472248217568028
   PubMed Web of Science ®Google Scholar
• GumboTDrusanoGLLiuWAnidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasisAntimicrob Agents Chemother200650369516954319
   PubMed Web of Science ®Google Scholar
• DowellJAStogniewMKrauseDHenkelTWestonIEAssessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporineJ Clin Pharmacol20054522723315647416
   PubMed Web of Science ®Google Scholar
• DowellJAStogniewMKrauseDHenkelTDamleBLack of pharmacokinetic interaction between anidulafungin and tacrolimusJ Clin Pharmacol20074730531417322142
   PubMed Web of Science ®Google Scholar
• HerbrechtRGrahamDSchusterMSafety and tolerability of combination anidulafungin (ANID) and liposomal amphotericin B (LAmB) for the treatment of invasive aspergillosis (IA)Tandem Bone Marrow Transplantation MeetingsOrlando, FLAmerican Society for Blood and Marrow Transplantation200491
   Google Scholar
• DowellJASchranzJBaruchAFosterGSafety and pharmacokinetics of coadministered voriconazole and anidulafunginJ Clin Pharmacol2005451373138216291712
   PubMed Web of Science ®Google Scholar